Navigation Links
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
Date:11/9/2008

- In Two Studies Drug was Well-Tolerated, Significantly Inhibited

Leukotriene Production, and Reduced Inflammation- - Webcast Conference Call to Discuss Results on Monday, November 10 at 8:30

a.m. ET-

NEW ORLEANS and SAN FRANCISCO, Nov. 9 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today the results of two Phase 2 studies of its lead drug, VIA-2291. In each Phase 2 study, VIA-2291 effectively inhibited production of leukotrienes, proposed mediators of vascular inflammation. VIA-2291 was generally well-tolerated. The results were presented today during a Special Session at the American Heart Association 2008 Scientific Sessions being held in New Orleans.

"These trials accomplished our goal of demonstrating that VIA-2291 directly impacts the leukotriene pathway and potentially reduces vascular inflammation, which we believe leads to atherosclerosis and death in a broad population," said Lawrence K. Cohen, Ph.D., chief executive officer of VIA Pharmaceuticals. "We now look forward to designing studies that can link VIA- 2291's unique mechanism of action to improvement in atherosclerotic plaque and ultimately cardiovascular outcomes."

The first of these trials, the acute coronary syndromes (ACS) trial, met its primary endpoint by demonstrating a significant change from baseline in Leukotriene B4 (LTB4) production at all doses tested (p<0.001).

The second trial, the carotid endarterectomy (CEA) trial, missed its primary endpoint of percentage reduction in macrophage inflammatory cells in plaque tissue, but met key secondary
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
10. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
11. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Feb. 10, 2011 ,We are in a State of ... message that concerned Florida residents are desperate for people to hear. ... day due to prescription drug abuse and statistics show it is ... (FAADA) is calling for an immediate Congressional hearing to help put ...
... Feb. 10, 2011 For the biopharmaceutical industry, ... - and difficulty - of interacting with patients ... have created both opportunities and challenges for approaching ... To help marketing teams in the ...
Cached Medicine Technology:Parents, Physicians Unite and Declare: State of Emergency 2Parents, Physicians Unite and Declare: State of Emergency 3Innovations in Patient-Focused Initiatives to Improve Outcomes 2
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... carcinoma but relatively few patients are cured. Combined neoadjuvant ... survival but there is concern about treatment morbidity and ... research team from China used a prospective study, based ... postoperative CRT to surgery alone in patients with resectable ...
... idiopathic skeletal hyperostosis (DISH) is a common but ... people. All papers related to DISH demonstrate a ... advancing age. Various local structural lesions such as ... cervical osteophytes may lead to mechanical esophageal dysphagia. ...
... beyond the liver, researchers say , FRIDAY, April 9 ... virus are at much higher risk of developing kidney ... than 67,000 patients enrolled in the Henry Ford Health ... with hepatitis C developed kidney cancer. That,s double the ...
... , FRIDAY, April 9 (HealthDay News) -- Nearly half ... school-aged children are due to overuse -- and many ... the message from the just-launched Stop Sports Injuries campaign, ... and elite athletes, including professional golf legend Jack Nicklaus; ...
... ... New York Clinical Information Exchange, based in Buffalo, NY, has selected the Anakam to ... ... 9, 2010 -- Anakam announced today that HEALTHeLINK the Western New York Clinical Information ...
... Singapore ... procedures. With success rates topping 90 percent across a range of complex surgeries, the country ... ... National Eye Centre (SNEC) is the first and only specialist eye centre outside of ...
Cached Medicine News:Health News:Perioperative chemoradiotherapy in esophageal squamous cell carcinoma 2Health News:More Kids Falling Prey to Sports Overuse Injuries 2Health News:More Kids Falling Prey to Sports Overuse Injuries 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 2Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 3Health News:HEALTHeLINK Selects ANAKAM To Provide Cloud Based Community Wide Two Factor Authentication 4Health News:Singapore Performs Cutting-edge Eye Surgeries 2Health News:Singapore Performs Cutting-edge Eye Surgeries 3Health News:Singapore Performs Cutting-edge Eye Surgeries 4Health News:Singapore Performs Cutting-edge Eye Surgeries 5
Female High Waist Briefs...
Provides upper and lower arm and flank support. Extends to the wrist and over the full upper back. Has a thin strap above the breast and a 3 waistband for a secure, comfortable fit. Made of soft span...
Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...
Sub Pectoral Breast Augmentation Wrap...
Medicine Products: